Brief: Aequus advances clinical development of Transdermal Aripiprazole Patch
17/10/2016 14:03
Oct 17 (Reuters) - Aequus Pharmaceuticals Inc AQS.V
* Aequus advances clinical development of Transdermal
Aripiprazole Patch
* Upon approval of CTA, Co plans to initiate repeat dose,
28-day safety, study of Aripiprazole Transdermal Patches in late
2016
Source text for Eikon: ID:nMKWgtLxRa
Further company coverage: AQS.V
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Aequus Pharmaceuticals
See all newsBrief: Aequus Pharmaceutical Canada Pauses Sales Of Evolve Intensive Eyedrops, Gel In Canada
Brief: Aequus Announces Financing To Support Launch Of Zimed Preservative Free (Bimatoprost 0.03%) And Board Update
Brief: Aequus Announces Health Canada Notice Of Compliance For Zimed® Preservative Free
Brief: Aequus Announces Sandoz Contract Expiry At Year End And Expected Health Canada Approval For Zimed® Pf (Preservative Free)
Brief: Aequus Resumes Trading On TSX Venture Exchange